In NSCLC, Trm (TIM-3+PD-1+CD103+) cells expressing proliferation (Ki67+) and cytotoxicity (GZMB+IFN-γ+TNF+IL-2+) markers are enriched after anti-PD-1 therapy (51, 52). Here, HAVCR2 is linked to non-small cell lung carcinoma.